EUCTR2009-016813-11-IT进行中（未招募）不适用
Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks) and esclusive temozolomide (TMZ)(200 mg/m2 for 5 days every 28) - AOBS-RT-TMZ
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA0 个研究点开始时间: 2010年1月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •histological diagnosis of glioblastoma prognostic classes RPA V and VI with age >= 65 yrs: Compliance to the treatment and to the follow-up; informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Absence of histological diagnosis of glioblastoma age <65 yrs class RPA III-IV previous neoplasia excluding intraepithelial ca of portio previous brain radiotherapy
研究者
相似试验
进行中（未招募）
1 期
Phase II study: drug exposure and safety of an shortened tuberculosis treatment based on higher doses of Rifampicin and PyrazinamideMedDRA version: 20.0Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsTuberculosisEUCTR2019-003721-25-SERegion Östergötland40
已完成
不适用
Prospective randomised phase II clinical trial of epirubicin, cisplatin, continuous infusional 5-fluorouracil (ECF) versus epirubicin, cisplatin and capecitabin (ECX) in patients with advanced gastric cancerCancerISRCTN72792659Ministry of Higher Education, Science and Technology (Slovenia)80
已完成
2 期
Efficacy of a new COVID-19 treatmentPACTR202006899597082Malagasy government60
进行中（未招募）
不适用
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
进行中（未招募）
不适用
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerEUCTR2012-003743-30-SEKarolinska University Hospital